MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Xencor Company Profile (NASDAQ:XNCR)

Consensus Ratings for Xencor (NASDAQ:XNCR) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.67 (64.01% upside)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
DateFirmActionRatingPrice TargetActions
5/2/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Leerink SwannLower Price TargetOutperform$22.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015FBR & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015WedbushReiterated RatingBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015MLV & Co.Reiterated RatingBuy$22.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit SuisseInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Xencor (NASDAQ:XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.17)($0.19)$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015($0.22)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3 14($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014($0.19)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Xencor (NASDAQ:XNCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.35)($0.21)($0.26)
Q2 20164($0.36)($0.23)($0.28)
Q3 20164($0.37)($0.24)($0.29)
Q4 20164($0.29)$0.06($0.19)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.28)($0.28)($0.28)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Xencor (NASDAQ:XNCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Xencor (NASDAQ:XNCR)
DateHeadline
06/14/16 07:09 AMXencor to Host Analyst Day and Webcast on June 28, 2016 - [at noodls] - MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
06/06/16 04:47 PMETF’s with exposure to Xencor, Inc. : June 6, 2016 -
05/28/16 02:27 PMXencor, Inc. (NASDAQ:XNCR) Impact Score At 0 - Investor Newswire - Xencor, Inc. (NASDAQ:XNCR) Impact Score At 0Investor NewswireAlpha One explored various online articles released on Xencor, Inc. (NASDAQ:XNCR), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/25/16 02:18 PMXencor, Inc. (NASDAQ:XNCR) EPS Estimate At $-0.3 - Stocks Daily - Xencor, Inc. (NASDAQ:XNCR) EPS Estimate At $-0.3Stocks DailyThe EPS projection of Xencor, Inc. (NASDAQ:XNCR) for quarter ended 2016-09-30 is $-0.3. A week earlier, the EPS target was $-0.3 against target of $-0.3, a month earlier. This target stood at $-0.3 60 days ago against estimate of $-0.3 90 days earlier.Were Analysts Bullish Xencor Inc (NASDAQ:XNCR) This Week?Wall Street Hints and Newsall 2 news articles »
05/24/16 12:39 AMEarnings Review and Stock Rundown for Xencor, Inc. (NASDAQ:XNCR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Xencor, Inc. (NASDAQ:XNCR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Xencor, Inc. (NASDAQ:XNCR) to post ...and more »
05/23/16 07:06 AMXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : May 23, 2016 -
05/18/16 11:32 AMXencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference - [at noodls] - MONROVIA, Calif., May 18, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
05/18/16 11:03 AM12:03 pm Xencor presents complete data results from phase 1a first-in-human study for XmAb7195 at the American Thoracic Society International Conference, XmAb7195 generally 'well tolerated' -
05/17/16 07:33 PMShare Recap and Earnings Focus on Xencor, Inc. (NASDAQ:XNCR) - Wall Street Hints and News - Share Recap and Earnings Focus on Xencor, Inc. (NASDAQ:XNCR)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Xencor, Inc.and more »
05/17/16 07:42 AMXencor to Present at Upcoming Investor Conferences - [at noodls] - MONROVIA, Calif., May 17, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
05/11/16 02:34 PMConsensus Rating Review for Xencor, Inc. (NASDAQ:XNCR) - B.O.D.Y Confidential - Consensus Rating Review for Xencor, Inc. (NASDAQ:XNCR)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Xencor, Inc. (NASDAQ:XNCR). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/11/16 09:22 AMXencor, Inc. :XNCR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 12:47 AMAfter Last Week What Do Analysts Think Of Xencor, Inc. (XNCR) - Share Trading News - After Last Week What Do Analysts Think Of Xencor, Inc. (XNCR)Share Trading News05/06/2015 – Xencor, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 14 price target on the stock. The share price of Xencor, Inc. (XNCR) was up +0.62% during the last trading session, with a day high of 11.44.
05/07/16 12:04 PMXENCOR INC Financials -
05/05/16 07:40 PMXencor Inc (XNCR) Drops 7.06% on May 04 - Equities.com - Xencor Inc (XNCR) Drops 7.06% on May 04Equities.comXencor Inc (XNCR) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 7.06% to $11.06, a loss of $-0.84 per share. Starting at an opening price of $11.79 a share, the stock traded between $10.96 and $11.79 over the ...Xencor Inc (XNCR) Forecasted to Post Q1 2017 Earnings of ($0.26) Per ShareWeb Breaking NewsBroker Roundup For Xencor, Inc. (XNCR)Share Trading Newsall 5 news articles »
05/05/16 02:33 PMXencor Inc (XNCR) is Trading Lower on Unusual Volume for May 03 - Equities.com - Xencor Inc (XNCR) is Trading Lower on Unusual Volume for May 03Equities.comXencor Inc (XNCR) experienced unusually high volume on May. 03, as the stock lost 3.49% to a closing price of $11.90. The stock saw 333,721 shares trade hands over the course of the day on 3,001 trades. Given that the stock's average daily volume over ...Were Analysts Bearish Xencor Inc (NASDAQ:XNCR) This Week?B.O.D.Y Confidentialall 3 news articles »
05/04/16 02:32 PMAverage Analyst Rating for Xencor, Inc. (NASDAQ:XNCR) - B.O.D.Y Confidential - Average Analyst Rating for Xencor, Inc. (NASDAQ:XNCR)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Xencor, Inc. (NASDAQ:XNCR) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 02:32 PMAnalysts See 62% Gains Ahead For XBI - Three of XBI's underlying holdings with notable upside to their analyst target prices are Xencor, Inc (XNCR), Vanda Pharmaceuticals Inc (VNDA), and Alder Biopharmaceuticals Inc (ALDR). Although XNCR has traded at a recent price of $11.79/share, the average ...
05/03/16 01:53 PMETF’s with exposure to Xencor, Inc. : May 3, 2016 -
05/03/16 12:48 AMNorthwest Bio Heading North, PRTK To Report Data In June, FLML Gets FDA Nod - TRVN closed Monday's trading at $7.63, down 2.05%. Xencor Inc. (XNCR) expects full results from a phase Ia trial of XmAb7195 for the treatment of severe asthma and allergic diseases this quarter. A phase I trial with a subcutaneous formulation of XmAb7195 ...
05/02/16 03:57 PMXencor reports 1Q loss -
05/02/16 03:30 PMXencor Reports First Quarter 2016 Financial Results - [at noodls] - MONROVIA, Calif., May 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
05/02/16 07:15 AMXencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : May 2, 2016 -
05/02/16 06:07 AMQ1 2016 Xencor Inc Earnings Release - After Market Close -
04/27/16 03:08 PMXENCOR INC Files SEC form 8-K, Change in Directors or Principal Officers -
04/27/16 02:34 PMXencor, Inc. (NASDAQ:XNCR) Share Rating Recap - B.O.D.Y Confidential - Xencor, Inc. (NASDAQ:XNCR) Share Rating RecapB.O.D.Y ConfidentialShares of Xencor, Inc. (NASDAQ:XNCR) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/27/16 02:34 PMAnalyst Review: Xencor, Inc. (XNCR) - Risers & Fallers - Web Breaking NewsAnalyst Review: Xencor, Inc. (XNCR)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Xencor, Inc. (XNCR). According to the latest broker reports outstanding on Wednesday 27th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Are Analysts Bearish Xencor Inc (NASDAQ:XNCR) After Last Week?Franklin IndependentXencor Inc (XNCR) Upgraded to "Hold" by TheStreetWeb Breaking Newsall 4 news articles »
04/25/16 07:19 AMXencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016 - [at noodls] - MONROVIA, Calif., April 25, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
04/24/16 02:36 PMXencor, Inc. (NASDAQ:XNCR) Reported Basic Consolidated EPS Of $-0.4509 - RealistInvestor.com - Xencor, Inc. (NASDAQ:XNCR) Reported Basic Consolidated EPS Of $-0.4509RealistInvestor.comThe basic EPS from continuing operations as reported by Xencor, Inc. (NASDAQ:XNCR) for the period ended 2015-12-31 was $-0.4509. For the quarter ended 2015-12-31, the respective number stood at $-0.4509. For any stock there may be numerous ...Xencor Incorporated (NASDAQ:XNCR) Shorted Shares Decreased By 5.05%The PostIs Xencor Inc's Fuel Running Low? The Stock Just Declined AgainFranklin Independentall 2 news articles »
04/22/16 02:35 PMXencor, Inc. (NASDAQ:XNCR) Analyst Rating Review - B.O.D.Y Confidential - Xencor, Inc. (NASDAQ:XNCR) Analyst Rating ReviewB.O.D.Y ConfidentialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for Xencor, Inc. (NASDAQ:XNCR). 3 have rated the stock a “Strong Buy”, ...and more »
04/21/16 07:40 PMXencor, Inc. (NASDAQ:XNCR) Share Rating Recap - The Post - Xencor, Inc. (NASDAQ:XNCR) Share Rating RecapThe PostShares of Xencor, Inc. (NASDAQ:XNCR) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/20/16 02:35 PMLatest Analyst Ratings For Xencor, Inc. (XNCR) - Share Trading News - Latest Analyst Ratings For Xencor, Inc. (XNCR)Share Trading NewsXencor, Inc. has a 50 day moving average of 13.03 and a 200 day moving average of 12.82. The stock's market capitalization is 580.04M, it has a 52-week low of 9.89 and a 52-week high of 24.82. The share price of the company (XNCR) was down -1.17%, ...
04/16/16 12:45 AMHottest Stories on Wall Street: Builders FirstSource (NASDAQ:BLDR), Pinnacle Foods Inc. (NYSE:PF), Xencor ... - Property Mentor - Hottest Stories on Wall Street: Builders FirstSource (NASDAQ:BLDR), Pinnacle Foods Inc. (NYSE:PF), Xencor ...Property MentorCanaccord Genuity reissued their buy rating on shares of Xencor Inc (NASDAQ:XNCR) in a report released on Monday morning, AnalystRatings.NET reports. They currently have a $20.00 price objective on the biopharmaceutical company's stock. Amyris, Inc.and more »
04/15/16 07:35 PMXencor, Inc. (NASDAQ:XNCR): Quick Look at Earnings - News Tribune - Xencor, Inc. (NASDAQ:XNCR): Quick Look at EarningsNews TribuneWhen Xencor, Inc. (NASDAQ:XNCR) issues their next quarterly report on or near 2016-05-02, Wall Street analysts are predicting they will report earnings per share of $-0.28. This consensus EPS number is provided by Zacks Research, which might differ ...and more »
04/15/16 07:35 PMXencor, Inc. (NASDAQ:XNCR) Analyst Recommendation Outlook - Clinton Financial - Xencor, Inc. (NASDAQ:XNCR) Analyst Recommendation OutlookClinton FinancialThere are 3 analysts providing ratings for Xencor, Inc. (NASDAQ:XNCR). 3 have given the stock a “Strong Buy”, 0 rate it a “Buy”, 0 are rating the stock a Hold, and 0 are recommending “Sell”. Every recommendation can be mapped to an integer based scale ...and more »
04/15/16 12:51 AMXencor Incorporated (NASDAQ:XNCR) Short Interest Increased By 2.5% - RiversideGazette.com - Xencor Incorporated (NASDAQ:XNCR) Short Interest Increased By 2.5%RiversideGazette.comThe short interest to Xencor Incorporated's float is 9.89%. The stock decreased 0.07% or $0.01 during the last trading session, hitting $14.73. About 132,584 shares traded hands. Xencor Inc (NASDAQ:XNCR) has declined 13.40% since September 9, 2015 ...
04/14/16 07:43 PMXencor Inc (XNCR) Jumps 5.14% on April 13 - Equities.com - Xencor Inc (XNCR) Jumps 5.14% on April 13Equities.comXencor Inc (XNCR) was among the biggest gainers on the Russell 2000 for Wednesday April 13 as the stock popped 5.14% to $14.74, representing a gain of $0.72 per share. Some 483,431 shares traded hands on 2,683 trades, compared with an average ...and more »
04/14/16 02:32 PMXencor Inc (XNCR) Insider Sells $56250.00 in Stock - Washington News Wire - Xencor Inc (XNCR) Insider Sells $56250.00 in StockWashington News WireXencor logo Xencor Inc (NASDAQ:XNCR) insider Edgardo Baracchini, Jr. sold 3,750 shares of Xencor stock in a transaction that occurred on Thursday, April 7th. The shares were sold at an average price of $15.00, for a total value of $56,250.00. Following ...Hottest Stories on Wall Street: Builders FirstSource (NASDAQ:BLDR), Pinnacle Foods Inc. (NYSE:PF), Xencor ...Property Mentorall 2 news articles »
03/29/16 04:30 PMETF’s with exposure to Xencor, Inc. : March 29, 2016 -
03/14/16 03:08 PMETF’s with exposure to Xencor, Inc. : March 14, 2016 -
03/10/16 10:41 AMXencor, Inc. :XNCR-US: Earnings Analysis: 2015 By the Numbers -
03/09/16 07:15 AMXencor (XNCR) Catches Eye: Stock Adds 6.9% in Session -
03/08/16 04:21 PMXENCOR INC Files SEC form 10-K, Annual Report -
03/08/16 02:11 PMEdited Transcript of XNCR earnings conference call or presentation 7-Mar-16 9:30pm GMT -
03/07/16 03:29 PMXencor beats Street 4Q forecasts -
03/07/16 03:07 PMXENCOR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/07/16 03:02 PMXencor Reports Fourth Quarter and Full Year 2015 Financial Results - [PR Newswire] - MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
03/07/16 03:01 PMXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus - [PR Newswire] - MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE). "We are advancing XmAb5871 in IgG4-RD and SLE because of its potent, reversible B-cell inhibition and promising treatment effect demonstrated in a Phase 1b/2a study of patients with rheumatoid arthritis, as well as previous ex vivo results with XmAb5871 showing inhibition of SLE patient B-cell activation and humoral immunity," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.
03/07/16 06:07 AMQ4 2015 Xencor Inc Earnings Release - After Market Close -
03/02/16 07:00 AMXencor to Present at Cowen and Company 36th Annual Health Care Conference - [PR Newswire] - MONROVIA, Calif., March 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
About Xencor

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XNCR
  • CUSIP:
Key Metrics:
  • Previous Close: $14.43
  • 50 Day Moving Average: $13.36
  • 200 Day Moving Average: $12.90
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $573.28M
  • Current Quarter EPS Consensus Estimate: $-0.90 EPS
Additional Links:
Xencor (NASDAQ:XNCR) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha